Ralph Niven, CHIEF SCIENTIFIC OFFICER at Aerovate Therapeutics, Inc. (AVTE), sold 4,455 shares at $23.73 ($106K) on 2023-03-06, disclosed to the SEC on 2023-03-08.
Open-market sale of $106k AVTE by CHIEF SCIENTIFIC OFFICER. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $23.73 | 2,205 | $52K | 49.5% |
| 2 | $23.73 | 2,205 | $52K | 49.5% |
| 3 | $24.92 | 45 | $1K | 1.1% |
| Total | $23.74 avg | 4,455 | $106K | 100% |
| Filing → |
| AVTE | SELL | 2023-12-07 | $75K | — | Filing → |
| AVTE | SELL | 2023-11-27 | $207K | — | Filing → |
| AVTE | SELL | 2023-07-07 | $39K | — | Filing → |